Praxis Precision Medicines (PRAX) Expected to Announce Earnings on Monday

Key Points

• Praxis Precision Medicines is expected to report Q3 2026 results before the market opens on November 9. Analysts forecast a loss of $3.54 per share and revenue of approximately $0.13 million.
• The company previously beat expectations, reporting a quarterly loss of $2.87 per share versus the consensus estimate of a $3.67 loss. Analysts project full-year and next-year losses of $14.15 and $11.79 per share, respectively.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and a $630.42 price target. PRAX opened at $285.93, compared with a 52-week range of $154.45 to $392.70.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Monday, November 9th. Analysts expect Praxis Precision Medicines to announce earnings of ($3.54) per share and revenue of $0.13 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.67) by $0.80. On average, analysts expect Praxis Precision Medicines to post ($14.15) EPS for the current fiscal year and ($11.79) EPS for the next fiscal year.

Praxis Precision Medicines Stock Performance

Shares of PRAX opened at $285.93 on Monday. Praxis Precision Medicines has a 52-week low of $154.45 and a 52-week high of $392.70. The business's 50 day moving average price is $301.28 and its two-hundred day moving average price is $314.42. The firm has a market cap of $7.98 billion, a PE ratio of -22.11 and a beta of 2.85.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Raymond James Financial reissued a "strong-buy" rating and set a $945.00 target price on shares of Praxis Precision Medicines in a research note on Monday, August 17th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $462.00 price target (up from $449.00) on shares of Praxis Precision Medicines in a research note on Friday, August 7th. Piper Sandler reiterated an "overweight" rating on shares of Praxis Precision Medicines in a report on Monday, July 13th. The Goldman Sachs Group reissued a "buy" rating and set a $575.00 price objective (up from $470.00) on shares of Praxis Precision Medicines in a research report on Friday, August 21st. Finally, Needham & Company LLC restated a "buy" rating and issued a $582.00 target price on shares of Praxis Precision Medicines in a research note on Thursday, September 24th. Three analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $630.42.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for disorders of the central nervous system. The company applies its Cerebrum™ platform, which combines human genetics, neuroscience and data science, to identify disease mechanisms and advance precision medicines for patients with neurological and psychiatric conditions.

Its pipeline has included investigational treatments for epilepsy and other severe neurological disorders. Key programs have included PRAX-628, a small-molecule antiseizure medicine candidate, and elsunersen, an antisense oligonucleotide program being developed for certain genetically defined forms of epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.